Can you get Mounjaro with a BMI under 30?

Does a BMI under 30 automatically rule out Mounjaro?

Not automatically, but it does rule out most people. The licensed indication for tirzepatide (Mounjaro) in the UK covers two groups: adults with a BMI of 30 or above, and adults with a BMI of 27–29.9 who also have at least one weight-related comorbidity. Below a BMI of 27, there is no licensed basis for prescribing it for weight management, and a responsible prescriber will not do so. This is the framework set by the UK medicines regulator based on the clinical evidence submitted at the time of licensing.

So if your BMI is, say, 28.5 and you have been told you have high blood pressure or pre-diabetes, you may well be in scope. If your BMI is 28.5 and you have no qualifying condition, you are not, at least not through the licensed route. The NHS BMI calculator is a reasonable first check if you are unsure of your own figure, and the specifics of the 27 BMI threshold are worth reading if you are close to that boundary.

One thing people sometimes overlook: ethnicity matters here. UK clinical guidance applies a 2.5 kg/m² reduction to these thresholds for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. In practice, that means a BMI of 27 becomes approximately 24.5 as the effective lower limit for the 27-plus-comorbidity group. A prescriber familiar with eligibility at the lower end of the BMI range will factor this in.

Which health conditions count when your BMI is between 27 and 30?

The conditions that can open the door at a lower BMI are ones with a documented link to excess weight. The Mounjaro prescribing framework, as reflected in its UK SmPC and reviewed by NICE's appraisal of tirzepatide (TA1026), points to conditions including type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and cardiovascular disease. These are the clearest examples, though the list is not rigidly closed, what matters is that the condition is weight-related and that a prescriber makes a clinical judgement about the benefit-to-risk balance for you specifically.

Pre-diabetes or non-alcoholic fatty liver disease could also be relevant depending on clinical context, though the strength of that evidence varies. Conditions that are not meaningfully linked to body weight (a broken wrist, for instance, or seasonal allergies) would not satisfy the criterion.

If you have an underactive thyroid and are wondering whether that changes things, the picture there is more nuanced and worth looking at separately. Thyroid conditions interact with weight management in specific ways that a prescriber will want to discuss.

It is also worth noting that having a qualifying condition does not guarantee that Mounjaro is the right choice. Some conditions or medicines may affect whether treatment is safe for you. A prescriber's job is to weigh all of that, not to apply a checklist mechanically.

What about people with a very low BMI who still feel they need support?

This is a question our prescribers encounter regularly, and it deserves a direct answer. If your BMI is below 27 and you do not have a qualifying weight-related condition, Mounjaro is not a route available to you through any legitimate UK prescriber. That is not a judgement about how you feel in your body; it reflects the boundaries of what the evidence supports and what is licensed.

There are other paths worth knowing about. Orlistat, for example, is licensed at a lower BMI threshold and available in different forms. Structured lifestyle programmes, dietitian support, and other clinical options exist. If you are weighing up what is actually available for your situation, the alternatives to Mounjaro page covers the landscape honestly. The weight-loss treatment overview also gives context on which approaches suit different starting points.

For people who sit just under 30 and are unsure whether they might qualify once a comorbidity is factored in, a consultation is the only way to find out. A prescriber can look at your individual circumstances in a way that a BMI calculator simply cannot. Worth knowing too: if you tend to sort these things out at the start of a new month (after payday, or before a holiday) booking a consultation early in the week means your records are reviewed while your prescriber has the full team around them.

Private Mounjaro treatment through a regulated pharmacy is not cheap, and that is by design. Understanding what Mounjaro costs in the UK (and what a legitimate price actually includes) helps set the right expectations before you start.

How does a prescriber make the final call?

BMI is a starting point, not the whole story. When a prescriber reviews your consultation, they are looking at your weight history, your current health conditions and how well they are managed, any medicines you already take, and whether there are any reasons treatment might not be safe. Conditions such as a personal or family history of medullary thyroid carcinoma, a history of pancreatitis, or certain gastrointestinal conditions would all be relevant. Pregnancy, breastfeeding, and actively trying to conceive are situations where Mounjaro is not recommended.

The NHS medicines page on tirzepatide gives a clear overview of the contraindications and cautions that any prescriber will be working through. It is written for patients and is worth reading before any consultation.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not an automated system) on the same day it is submitted. They apply exactly this framework: your BMI, your qualifying conditions if any, your full health picture. If you are close to the 27–30 range and unsure whether a condition you have might qualify, the free consultation is the place to find out. You can explore how Mounjaro works and what treatment involves, then learn more about our clinical team before deciding whether to go ahead. There is no pressure and no charge simply for having your case assessed.